Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Caloric Restriction Slows Age-Related Loss of Neurons by Activating SIRT1

By BiotechDaily International staff writers
Posted on 06 Jun 2013
Image: Senior author Dr. Li-Huei Tsai (Photo courtesy of the Massachusetts Institute of Technology).
Image: Senior author Dr. Li-Huei Tsai (Photo courtesy of the Massachusetts Institute of Technology).
Image: To delay the onset of neurodegeneration, mice have the option to undergo a regimen of caloric restriction (represented by the scale) or a pharmacological treatment with a SIRT1-activation compound (tube labeled SRT), both of which result in reduced memory loss and preserved synaptic plasticity (Photo courtesy of Dr. Li-Huei Tsai, Massachusetts Institute of Technology).
Image: To delay the onset of neurodegeneration, mice have the option to undergo a regimen of caloric restriction (represented by the scale) or a pharmacological treatment with a SIRT1-activation compound (tube labeled SRT), both of which result in reduced memory loss and preserved synaptic plasticity (Photo courtesy of Dr. Li-Huei Tsai, Massachusetts Institute of Technology).
Caloric restriction (CR), a dietary regimen known to promote lifespan by retarding the onset of age-dependent diseases, has been found to slow the progressive loss of neurons associated with impaired cognitive capacity by activating the enzyme sirtuin 1 (SIRT1, silent mating type information regulation 2 homolog 1).

Investigators at the Massachusetts Institute of Technology (Cambridge, USA) speculated that since aging is the greatest risk factor for neurodegeneration in the brain, CR might slow the progressive loss of neurons. To explore this possibility they used a genetically engineered mouse model that allowed for temporally and spatially controlled onset of neurodegeneration. These animals were fed a diet decreased by 30% from the normal mouse diet for three months.

Results published in the May 22, 2013, issue of the Journal of Neuroscience revealed that CR significantly delayed the onset of neurodegeneration and synaptic loss and dysfunction, and thereby preserved cognitive capacities.

“We not only observed a delay in the onset of neurodegeneration in the calorie-restricted mice, but the animals were spared the learning and memory deficits of mice that did not consume reduced-calorie diets,” said senior author Dr. Li-Huei Tsai, professor of brain and cognitive sciences at the Massachusetts Institute of Technology. “The question now is whether this type of treatment will work in other animal models, whether it is safe for use over time, and whether it only temporarily slows down the progression of neurodegeneration or stops it altogether



Channels

Drug Discovery

view channel
Image: Scanning electron microscope (SEM) image of a field of polypyrrole nanowires (Photo courtesy of Dr. Richard Borgens, Purdue University).

Novel Controlled-Release Drug Delivery System Heals Spinal Inflammation in Mouse Model

A novel drug delivery system that allows controllable release of an anti-inflammatory agent directly to the site of inflammation or injury was tested successfully in a mouse model. Investigators at... Read more

Therapeutics

view channel
Image: A photmicrograph of medium spiny neurons (yellow) with nuclear inclusions (orange), which occur as part of the Huntington\'s disease process. Several neurons are colored yellow and have a large central core with up to two dozen tendrils branching out of them. The core of the neuron in the foreground contains an orange blob about a quarter of its diameter (Photo courtesy of Wikimedia Commons).

Seeding Assay May Boost Search for Huntington's Disease Drugs

An assay technique that measures seeding of mutant huntingtin aggregates in cerebral spinal fluid (CSF) may identify individuals with Huntington's disease (HD) that have not yet become symptomatic and... Read more

Business

view channel

Biopharm Startup to Commercialize Antibody Therapy for Drug Resistant Cancers

A biopharm startup company has licensed the rights to commercialize an antibody-based approach for treatment of drug resistant cancers. The new company, CadheRx Therapeutics (La Jolla, CA, USA), entered into a licensing agreement with Stony Brook University (NY, USA) to develop and market an anticancer technology derived... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.